Developer docs
API playgroundTry for free, no card

Search company profiles

Kurma Partners

Full company profile

uuid00003na

Namestring
Kurma Partners
Legal namestring
Kurma Partners
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Kurma Partners is a Paris-based venture capital firm founded in 2009 that specializes in financing healthcare and biotechnology innovation across Europe. The firm has financed 72 companies and founded 25 companies since inception, focusing on company creation from European academic research — it partners with leading institutions including Institut Pasteur, Inserm Transfert, SATT Paris-Saclay, IRB Barcelona, VIB, and Cancer Research UK to identify disruptive discoveries and assemble the scientific, entrepreneurial, and capital resources required to spin out therapeutics, diagnostics, and medical-device companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funds, biotech investments, healthcare financing, life sciences venture, company creation studio
Industry2 codes
PRIMARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SECONDARYFSANAHAE
Joint Venture CVC / Consortium Funds (Multi-corporate)
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital - Healthcare and Biotechnology
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Kurma Biofund
Description

Therapeutic venture franchise investing from pre-seed stage to growth capital in life sciences companies

kurmapartners.com
+3 more records
Core offering1 text field

Kurma Partners is a Paris-based venture capital firm that finances healthcare and biotechnology innovation in Europe across the company lifecycle, from academic spin-out creation through growth capital. It manages multiple specialized fund vehicles (therapeutic Biofund series, Diagnostics franchise, Growth Opportunities Fund) totaling approximately €1 billion in assets under management, and operates the Argobio Studio startup launchpad in partnership with leading European research institutions to build biotech companies from scientific discoveries.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Kurma Partners is a Paris-based venture capital firm and Eurazeo Group company that operates as a major player in European healthcare and biotechnology financing. The firm manages multiple specialized investment funds totaling €1 billion in assets under management across its franchises. Its core offering includes therapeutic venture funds (Biofund series), a healthtech diagnostics fund (Kurma Diagnostics), and a growth-stage fund (Kurma Growth Opportunities). Additionally, the firm operates Argobio Studio, a biotech startup launchpad in partnership with leading European research institutions. Since 2009, Kurma has financed 72 companies and founded 25 companies, leveraging partnerships with top European academic research centers including Institut Pasteur, INSERM, and Paris Saclay to transform disruptive scientific discoveries into cutting-edge medicines and medical devices.

Product and service6 records
1Kurma Biofund IV
CategoryVenture Capital Fund
Description

A €215 million venture capital fund focused on European biotech investments targeting disruptive therapeutic solutions for severe or incurable diseases, with approximately 80% allocated to therapy development and up to half directed toward companies established by Kurma or its ArgoBio Studio launchpad. Intended for institutional and strategic limited partners.

2Kurma Growth Opportunities Fund
CategoryVenture Capital Fund
Description

A growth-stage investment fund within Kurma Partners' franchise that supports later-stage European healthcare and biotech companies, with €160 million in first close commitments and a €250 million target. Intended for institutional limited partners.

3Kurma Diagnostics II (KDx2)
CategoryVenture Capital Fund
Description

An €83 million healthtech-focused venture fund, the only investment vehicle wholly dedicated to financing early-stage European innovative medical diagnostic companies, with a focus on deeptech firms specializing in disruptive molecular diagnostic tools. Intended for institutional limited partners.

4Kurma Biofund III
CategoryVenture Capital Fund
Description

A €160 million therapeutic venture fund, the third in Kurma's Biofund series, focused on life sciences investments from pre-seed to growth stages. Intended for institutional limited partners.

5Paris Saclay Seed Fund
CategoryVenture Capital Fund
Description

An early-stage seed fund associated with the Paris Saclay ecosystem, focused on financing innovative healthcare and biotech startups originating from the Paris Saclay research cluster. Intended for portfolio companies and co-investors.

6Argobio Studio
CategoryStartup Studio/Incubator
Description

A French biotech startup studio created in partnership with Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and Institut Pasteur, aiming to create at least five high-potential biotechnology companies over five years with €50 million in initial funding. Targeted at academic researchers and entrepreneurs seeking to build biotech companies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-23
Description

Strategic partnership for development and manufacturing of biologics for Kurma's portfolio companies. Samsung Biologics to provide derisking, development, manufacturing services and seamless transitions for biologics from early stages of development to large scale commercialisation. The partnership streamlines gene to IND process to accelerate lead candidate selection.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key academic partner for company creation, including PathoQuest and other companies

3Inserm Transfert
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partner in the network

kurmapartners.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nordic-European specialist biotech VC investing across stages. Comparable in mandate, stage range, and orientation toward therapeutic company creation.

TypeDirect peer
Description

Paris-based European healthcare and biotech VC with a multi-stage strategy spanning early-stage company creation to growth. Directly comparable in mandate, stage focus, and European geographic footprint.

TypeDirect peer
Description

Leading European biotech VC managing multiple fund vehicles across development stages. Comparable as a specialized life-sciences investor with similar AUM scale and pan-European deal sourcing.

TypeDirect peer
Description

Paris-based European healthcare and biotech investor. Direct peer — co-invested with Kurma in Adcytherix and Alveus Therapeutics and operates a similar Life Sciences strategy.

TypeDirect peer
Description

European healthcare-focused VC led by Sabine Dandiguian, investing in biotech across development stages. Directly comparable in stage range and European focus, and a co-investor with Kurma in Alveus Therapeutics.

TypeDirect peer
Description

Boston-based healthcare and biotech investment firm with global mandate. Comparable as a specialist life-sciences investor; co-led the Alveus Therapeutics Series A alongside Kurma's participation.

TypeDirect peer
Description

European life-sciences and technology VC. Comparable as a multi-stage European healthcare investor and recurring co-investor with Kurma in NUCLIDIUM.

TypeBroad incumbent
Description

Holding company of the Novo Nordisk Foundation managing multi-billion healthcare and biotech investments globally. Comparable as a large-scale healthcare investment platform; participated in Alveus Therapeutics alongside Kurma.

TypeBroad incumbent
Description

French sovereign investment bank with large healthcare and biotech investment operations. Comparable as a major French life-sciences investor and recurring co-lead/lead (Adcytherix) and cornerstone LP (Biofund IV) of Kurma.

TypeEmerging player
Description

European biotech VC investing in private early-stage drug development companies. Comparable in stage focus and therapeutic orientation, and a co-investor with Kurma in Adcytherix.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment132 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kurma Partners

Venture Capital - Healthcare and Biotechnologykurmapartners.com

What Kurma Partners does

Kurma Partners is a Paris-based venture capital firm founded in 2009 that specializes in financing healthcare and biotechnology innovation across Europe. The firm has financed 72 companies and founded 25 companies since inception, focusing on company creation from European academic research — it partners with leading institutions including Institut Pasteur, Inserm Transfert, SATT Paris-Saclay, IRB Barcelona, VIB, and Cancer Research UK to identify disruptive discoveries and assemble the scientific, entrepreneurial, and capital resources required to spin out therapeutics, diagnostics, and medical-device companies.

Kurma Partners firmographics

Firmographics
Name
Kurma Partners
Legal name
Kurma Partners
Website
https://kurmapartners.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Kurma Partners industry classification

Industry
Product category
Venture Capital - Healthcare and Biotechnology
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SECONDARYFSANAHAE
Joint Venture CVC / Consortium Funds (Multi-corporate)

Keywords

  • Venture capital funds
  • Biotech investments
  • Healthcare financing
  • Life sciences venture
  • Company creation studio

Where Kurma Partners is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Kurma Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels1 record

Marketing channels4 records

Kurma Partners product offering

Product offering

Core offering

Kurma Partners is a Paris-based venture capital firm that finances healthcare and biotechnology innovation in Europe across the company lifecycle, from academic spin-out creation through growth capital. It manages multiple specialized fund vehicles (therapeutic Biofund series, Diagnostics franchise, Growth Opportunities Fund) totaling approximately €1 billion in assets under management, and operates the Argobio Studio startup launchpad in partnership with leading European research institutions to build biotech companies from scientific discoveries.

Product overview

Kurma Partners is a Paris-based venture capital firm and Eurazeo Group company that operates as a major player in European healthcare and biotechnology financing. The firm manages multiple specialized investment funds totaling €1 billion in assets under management across its franchises. Its core offering includes therapeutic venture funds (Biofund series), a healthtech diagnostics fund (Kurma Diagnostics), and a growth-stage fund (Kurma Growth Opportunities). Additionally, the firm operates Argobio Studio, a biotech startup launchpad in partnership with leading European research institutions. Since 2009, Kurma has financed 72 companies and founded 25 companies, leveraging partnerships with top European academic research centers including Institut Pasteur, INSERM, and Paris Saclay to transform disruptive scientific discoveries into cutting-edge medicines and medical devices.

Differentiator

Problem solved

Functional benefit

Brands

  • Kurma Biofund: Therapeutic venture franchise investing from pre-seed stage to growth capital in life sciences companies
  • Kurma Diagnostics
  • Kurma Growth Opportunities Fund
  • ArgoBio Studio

Products and services

  • Kurma Biofund IV A €215 million venture capital fund focused on European biotech investments targeting disruptive therapeutic solutions for severe or incurable diseases, with approximately 80% allocated to therapy development and up to half directed toward companies established by Kurma or its ArgoBio Studio launchpad. Intended for institutional and strategic limited partners.
  • Kurma Growth Opportunities Fund A growth-stage investment fund within Kurma Partners' franchise that supports later-stage European healthcare and biotech companies, with €160 million in first close commitments and a €250 million target. Intended for institutional limited partners.
  • Kurma Diagnostics II (KDx2) An €83 million healthtech-focused venture fund, the only investment vehicle wholly dedicated to financing early-stage European innovative medical diagnostic companies, with a focus on deeptech firms specializing in disruptive molecular diagnostic tools. Intended for institutional limited partners.
  • Kurma Biofund III A €160 million therapeutic venture fund, the third in Kurma's Biofund series, focused on life sciences investments from pre-seed to growth stages. Intended for institutional limited partners.
  • Paris Saclay Seed Fund An early-stage seed fund associated with the Paris Saclay ecosystem, focused on financing innovative healthcare and biotech startups originating from the Paris Saclay research cluster. Intended for portfolio companies and co-investors.
  • Argobio Studio A French biotech startup studio created in partnership with Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and Institut Pasteur, aiming to create at least five high-potential biotechnology companies over five years with €50 million in initial funding. Targeted at academic researchers and entrepreneurs seeking to build biotech companies.

Companies that use Kurma Partners

Customer profile

Segments3 records

Ideal customer profiles4 records

Kurma Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Kurma Partners partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Samsung BiologicscoreStrategic or Co-development Partner · 23 October 2023Strategic partnership for development and manufacturing of biologics for Kurma's portfolio companies. Samsung Biologics to provide derisking, development, manufacturing services and seamless transitions for biologics from early stages of development to large scale commercialisation. The partnership streamlines gene to IND process to accelerate lead candidate selection.
  • Institut PasteurcoreStrategic or Co-development PartnerKey academic partner for company creation, including PathoQuest and other companies
  • Inserm TransfertcoreStrategic or Co-development PartnerAcademic research partner in the network

Scale indicators6 records

Recent moves4 records

Expansion highlights5 records

Kurma Partners competitors and assessment

Company assessment

Direct peers

  • HealthCap: Nordic-European specialist biotech VC investing across stages. Comparable in mandate, stage range, and orientation toward therapeutic company creation.
  • Sofinnova Partners: Paris-based European healthcare and biotech VC with a multi-stage strategy spanning early-stage company creation to growth. Directly comparable in mandate, stage focus, and European geographic footprint.
  • Forbion: Leading European biotech VC managing multiple fund vehicles across development stages. Comparable as a specialized life-sciences investor with similar AUM scale and pan-European deal sourcing.
  • Andera Partners: Paris-based European healthcare and biotech investor. Direct peer — co-invested with Kurma in Adcytherix and Alveus Therapeutics and operates a similar Life Sciences strategy.
  • Jeito Capital: European healthcare-focused VC led by Sabine Dandiguian, investing in biotech across development stages. Directly comparable in stage range and European focus, and a co-investor with Kurma in Alveus Therapeutics.
  • Omega Funds: Boston-based healthcare and biotech investment firm with global mandate. Comparable as a specialist life-sciences investor; co-led the Alveus Therapeutics Series A alongside Kurma's participation.
  • Wellington Partners: European life-sciences and technology VC. Comparable as a multi-stage European healthcare investor and recurring co-investor with Kurma in NUCLIDIUM.

Broad incumbents

  • Novo Holdings: Holding company of the Novo Nordisk Foundation managing multi-billion healthcare and biotech investments globally. Comparable as a large-scale healthcare investment platform; participated in Alveus Therapeutics alongside Kurma.
  • Bpifrance: French sovereign investment bank with large healthcare and biotech investment operations. Comparable as a major French life-sciences investor and recurring co-lead/lead (Adcytherix) and cornerstone LP (Biofund IV) of Kurma.

Emerging players

  • Pureos Bioventures: European biotech VC investing in private early-stage drug development companies. Comparable in stage focus and therapeutic orientation, and a co-investor with Kurma in Adcytherix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Kurma Partners social profiles

Digital presence

Kurma Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kurma Partners leadership team

Management profile

Number of profiles

Profiles8 records

Kurma Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kurma Partners M&A and investment

M&A and investment

M&A

Investments132 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kurma Partners

What does Kurma Partners do?

Kurma Partners is a Paris-based venture capital firm that finances healthcare and biotechnology innovation in Europe across the company lifecycle, from academic spin-out creation through growth capital. It manages multiple specialized fund vehicles (therapeutic Biofund series, Diagnostics franchise, Growth Opportunities Fund) totaling approximately €1 billion in assets under management, and operates the Argobio Studio startup launchpad in partnership with leading European research institutions to build biotech companies from scientific discoveries.

Is Kurma Partners a public or private company?

Kurma Partners is a private company. It is classified as corporate owned and is currently operating.

When was Kurma Partners founded?

Kurma Partners was founded in 2009. It employs 11 to 50 people.

Where is Kurma Partners based?

Kurma Partners is headquartered in Paris, France, in the Europe region.

Who are Kurma Partners's main competitors?

Direct peers on record are HealthCap, Sofinnova Partners, Forbion, Andera Partners, Jeito Capital, Omega Funds and Wellington Partners. Broad incumbents are Novo Holdings and Bpifrance. Pureos Bioventures is listed as an emerging player.

Does Kurma Partners have an API?

No public API is recorded for Kurma Partners.

What industry is Kurma Partners in?

Kurma Partners's product category is Venture Capital - Healthcare and Biotechnology. Its primary akta.pro industry code is FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures), with a secondary code of FSANAHAE, Joint Venture CVC / Consortium Funds (Multi-corporate). Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European Biotechnology8 European VC firms to watch in 2026Eight European VC firms are profiled for 2026, including Jeito Capital, Sofinnova Partners, and Medicxi, with fund sizes and recent exits. The list highlights firms that closed new biotech funds in the past year, such as Jeito II at $1.2 billion and Medicxi V at €500 million. The firms are positioned as shaping the continent's investment landscape amid tighter capital.BioSpaceFrance’s biotech ambition is strong but its scale-up engine still needs workFrance has strong government backing and scientific infrastructure for biotech, including the €7 billion Health Innovation 2030 plan and generous R&D tax incentives up to 30%, yet faces challenges converting research into investable companies due to limited company-building infrastructure and capital shortages at growth stages. Two Paris-based venture capital firms, Kurma Partners and Jeito Capital, recently closed significant funds — €215 million and over €1 billion respectively — to support European biotech startups, with Jeito's fund representing the largest raise by an independent European biopharma fund. The investors expressed optimism that Europe is gradually transforming and building the capital continuum needed to compete with the U.S.FinSMEsTacalyx Raises €11M in Seed Extension FundingTacalyx, a Berlin-based biotech, raised €11M in seed extension funding from backers including Boehringer Ingelheim Venture Fund and Eurazeo. The company will use the funds to advance TCX-201, an antibody drug conjugate against an undisclosed TACA, through preclinical development.BioSpaceTacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the ClinicTacalyx selected its first clinical candidate, TCX-201, an ADC targeting a TACA, and secured €11 million in a seed extension round. The company plans to file a clinical trial application in 2027 and expand the round with additional investors.BioCenturyNew targets at AACR, biopharma deals, Kurma fund — a BioCentury podcastBioCentury's latest podcast discusses more than 175 new oncology targets identified at the American Association for Cancer Research annual meeting in San Diego, focusing on enhancing immune response against solid tumors and improving existing immunotherapies, along with emerging pan-RAS inhibiting antibody-drug conjugates. The podcast also covers Eli Lilly's acquisition of a JAK-2 inhibitor from Ajax Therapeutics, Kurma Partners' new venture fund, and Elevara Medicines Ltd., a U.K.-based rheumatoid arthritis company. Analysts assess what the current pace of M&A and partnerships indicates about the state of biopharma dealmaking.BioSpaceNuevocor Appoints Dr. Monica Shah as Chief Medical OfficerNuevocor appointed Dr. Monica Shah as Chief Medical Officer to lead global clinical development and medical affairs. The company plans to initiate a first-in-human clinical trial of NVC-001 in LMNA-associated dilated cardiomyopathy in 2026. Dr. Shah brings over two decades of cardiovascular and gene therapy experience.MedCity NewsVC Firm Kurma Partners Closes €215M Fund in Pursuit of ‘Disruptive Therapeutic Solutions’Paris-based biotechnology venture capital firm Kurma Partners has closed its fourth and largest fund, Biofund IV, with €215 million in fresh capital, falling short of its €250 million target but marking a significant increase from its €160 million third fund. The new fund will deploy capital across up to 20 life sciences companies focused on developing disruptive therapeutic solutions for severe or incurable diseases, with about 80% allocated to therapy development and up to half directed toward companies established by Kurma or its startup launchpad ArgoBio Studio. With this close, Kurma's assets under management now total €1 billion, and its cornerstone investors include CSL Limited, the European Investment Fund, and Bpifrance.Pulse 2.0Kurma Partners: €215 Million Biofund IV Closes As Total AUM Reach €1 BillionKurma Partners, a Paris-based healthcare venture capital firm and Eurazeo group company, has announced the final closing of Biofund IV at €215 million, bringing its total assets under management across all franchises to €1 billion. The fund represents a 35% increase over its predecessor Biofund III and is backed by cornerstone investors including CSL, the European Investment Fund, and Bpifrance. The firm has already completed 11 investments through the fund and has demonstrated exits to major pharmaceutical groups including AstraZeneca, Eli Lilly, and uniQure.The Pharma LetterKurma closes 215 million euro Biofund IVKurma Partners closed its fourth life sciences fund, Biofund IV, at 215 million euros ($234 million), below its 250 million-euro target. The fund is nearly 35% larger than Biofund III, which raised 160 million euros in 2020.EU-StartupsKurma Partners closes €215 million Biofund IV to back European BioTech ventures from ParisKurma Partners, a French healthcare venture capital firm, announced the final closing of Biofund IV at €215 million, representing a 35% increase over its predecessor Biofund III. The fund is backed by three cornerstone investors: Australian pharmaceutical company CSL, the European Investment Fund, and Bpifrance, and brings Kurma Partners' total assets under management to €1 billion. The firm plans to make approximately 20 investments through Biofund IV, focusing on both startups and ex-nihilo company creation in European biotech, with 11 investments already completed.